simulates the occurrence of cervical cancer in this population, using different assumptions concerning natural history. This allows, in effect, the comparison of input and outcomes of different interventions in similar populations, in an analogy with a series of (very large) clinical trials.
Cervical cytology screening is undoubtedly effective in reducing the incidence of invasive carcinoma and in preventing subsequent death and disability. However, there is disagreement on the most satisfactory screening policy which should be employed, even within a single population such as that of England and Wales. There are many considerations to bear in mind, the most important of which is the natural history of the disease in terms of the incidence rate and sojourn-time of the pre-invasive stages of disease, and their variation with age, which can be used in mathematical models to estimate the apparently optimal spacing of a given number of screening tests."q In addition, however, several other factors influence the precise policy adopted. These include epidemiological knowledge of groups of the population at potentially higher risk of abnormalities of the cervix (eg, women attending family planning or gynaecological clinics), practical considerations such as the opportunity to examine women who might not normally attend for screening (eg, during or soon after pregnancy), and often intuitive judgements about the desirability of different outcomes. An example of the latter is the evident concern engendered by relatively few cases of cervical cancer in young women45 compared with the ineffectiveness of the current screening programmes in preventing disease in the elderly.6
In this paper we compare the predicted results of implementing several different screening policies which have been recommended for England and Wales since 1965. This was done using a computer simulation model which reproduces the demographic structure of the female population of England and Wales over a 30-year period (1961-90) and simulates the occurrence of cervical cancer in this population, using different assumptions concerning natural history. This allows, in (1) The incidence of dysplasia was weighted Is. For the present study, two sets of according to the relative risk of preclinical disease by tes were used, corresponding to the marital status and parity.1" The changing pattern of ries Hi and H3 previously described.9 marriage and divorce and, to a much lesser extent, .l histories are quite different, yet both childbearing during the 30-year period 1961-90 e observed prevalence of preclinical results in increasing prevalence of preclinical disease ige specific incidence rates observed in and a progressive increase in incidence.9 However, Wales in the early 1960s, before the observed changes in the shape of the age-specific is introduced. In both, dysplasia is a incidence curve are not well reproduced by this dition-75-800%0 of cases regress-and method.
uration is only two years. However, the (2) For each five-year birth cohort, the transfer ry of carcinoma in situ is very different, rates from normal to dysplasia were multiplied by a Figure 1 . cohort factor, c. For simulation of screening related to contraceptive advice (or spontaneous demand) the same parameters as Policy 3 were used, that is, an annual probability of 0-13 (starting at age 16) with prevalence of abnormality in attenders double that in non-attenders. Screening is stopped at age 65 for women with two consecutive negative smears.
For comparison with the seven "recommended" policies, the results from two very simple schedules of tests were studied:
(8) Five-yearly tests from age 25 to 65 (maximum of nine per lifetime); (9) Three-yearly tests from 25 to 64 (maximum of 14 per lifetime).
All of the policies tested comprise mixtures of "incidental" tests (taken during attendance for some other purpose) and "routine" tests at predetermined intervals. We examined the above policies under two assumptions of attendance for routine testing-that 80%. of those invited would attend and that 50%. would do so. We also assumed, in accordance with observation,22 that a proportion of individuals with screen-detected disease escape adequate follow-up or treatment; the proportions were 0-08 for dysplasias and 0 04 for carcinoma in situ, for three years after detection (one-fifth and one-tenth of the totals, respectively). fig 3; all of the natural histories used show increases, although these are progressive throughout the period in the marital/parity weighted histories, whereas the cohort-weighted histories show a rise in incidence rates only in the second half of the simulation period. In reality, incidence and mortality in England and Wales have fallen progressively since 1961, although this is in large measure due to screening, without which a rise would have occurred.6 Study of the change in age-specific incidence rates during the period of simulation shows that the cohort-weighted natural histories reproduce some of the features expected in the population if no screening had occurred, especially the striking rise in incidence in young women (fig 4) . The marital/parity weighted histories do not produce this change in shape of the age-specific incidence curve, which remains similar in configuration to that of 1966.
RESULTS OF SCREENING Table 1 shows the number of tests performed with the nine different policies at two levels of attendance for routine testing, and the proportion that are incidental tests (assumed to have only half the cost).
Since the specificity of the screening tests was set at 99*5%,, the number of false-positive examinations resulting from screening is 0 51% of the total number of tests. -------------H3C. ( fig 1) ; with H3 there are relatively few in-situ lesions with very short sojourn times that are able to progress to invasive disease in the inter-screening intervals. (5) performs moderately well, its efficiency at high attendance rates is third in rank (after the low intensity policies), and fourth when attendance for routine screening is 50%. Under the assumptions shown in tables 4 and 5 the addition of screening of symptomatic women (CGC+, policy 6) leads to a fall in the cost-effectiveness ratio. This is partly because of the increase in preclinical cases (especially dysplasia) which are detected and require treatment, the costs of which are usually sufficient to offset the moderate reductions in clinical cancers and deaths.
When attendance rates for routine screening are low, the simple BSCC policy (3) scores well in efficiency. It is interesting to compare this policy, which, in effect, adds three screenings to the simple MOH policy (incidental tests around 25-29, rescreen at 30, and a test at age 70) with policy 8, which adds two routine screens (at ages 25 and 30) to the simple MOH policy. The marginal gains from the additional routine tests in young women are small (2-4% increase in lives saved, 9-11 % in life-years, depending on attendance rates). The BSCC schedule has the advantage of testing young women at higher than average risk (family planning attenders) and adding a test in older women, whose risk of disease is still high. The additional costs incurred by the discovery of more preclinical lesions is offset by the fall in the number of cases of clinical invasive cancer that require treatment.
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The differences between screening with a three-yearly interval between tests compared to five-yearly can be seen by comparing policies 8 and 9. Firstly, it is clear that screening five-yearly with an 800% attendance rate results in fewer cases, deaths and person-years of life lost than screening three-yearly with 50%, attendance. The differences in cost-effectiveness are, however, small. With constant attendance rates, increasing frequency of testing leads to a 55%, increase in the number of tests performed, but this is accompanied by a much smaller increase in the number of lives saved during the 30 year period (10-14%,, depending on natural history and attendance rate). The cost of implementing the more intensive policy is also increased by the need to investigate and treat the additional positives generated by more frequent testing (although at low attendance rates this extra cost is offset by the reduction in cost of treatment of clinical cancer cases). The cost-effectiveness ratios are thus 15-30% lower (depending on the index chosen). The differences between the two BSCC policies (3 and 4) are rather small, since the more frequent schedule of testing in the BSCC+ policy begins only after the age of 35.
The calculation of cost-effectiveness ratios using the lower unit costs can be done using the data presented in tables 1, 4, and 5. All of the values for savings per 1000 units of input are increased, the size of this increase depending on the numbers of preclinical lesions and invasive cancers that require treatment. Thus the rankings of the different policies, and the relative differences between them, remain almost unchanged.
The comparisons between the different policies above have been made in terms of their costs and savings relative to those incurred over a 30-year period during which absolutely no screening activity is undertaken. It could be argued that this is an unrealistic baseline, since even in the absence of any screening programme, cytological examinations are often carried out on women attending medical services with gynaecological symptoms. Although such examinations can be regarded as a form of selective screening (searching for unrecognised disease in a known high risk group), in practice they are usually considered to be diagnostic tests. We have therefore considered the results of the different screening policies against a background of "diagnostic testing", making the assumption that the rate of such testing is one half that used for gynaecology testing in policy 6 (see methods), and that the rate of abnormality in women receiving such tests is three times that in the general population.
Over the 30-year simulation period, this diagnostic testing gave rise to the 33 500 cytological tests. Using Only the outcomes observed during the 30 years of screening have been included in the evaluation, along with the costs incurred during this period. Although the benefits of a screening programme will continue to accrue after the actual screening has ceased, we have not included these in the evaluation. It is most unlikely that cervix cancer screening will ever be stopped, so that post-programme evaluation is a rather theoretical idea. Furthermore, there is no reason to suppose that, in relation to the policies examined here, addition of post-screening benefits would make any difference to their relative efficiency. Since the items contributing to the costs (tests, follow-up investigations, treatment) are spread over the entire period, the total cost has been reckoned at constant prices, with no attempt at discounting to a base year. Two sets of costs were examined, with almost no effect on the relative cost-effectiveness of the different policies. Cytology'021 seems to be unsatisfactory, based on the criteria that we have adopted here. The concentration of screening at young ages, even though such tests may be less costly than usual (eg, in pregnancy) and involve higher risk groups (contraceptive users), leads to high costs for relatively small gains in outcome. It may be that this relative inefficiency will be less marked in the longer term if the incidence of disease in young women continues to rise at rates even more marked than those incorporated in this simulation (fig 4) . Nevertheless the wisdom of concentrating screening tests at young ages, as in Canada (the latest recommendations suggest 18 tests up to age of 35 and five thereafter37), must be seriously questioned. The rationale is presumably to ensure that some women who may not volunteer to start a screening programme will receive at least a first test during a visit for another purpose and may thereafter be more readily induced to re-attend. It might reasonably be questioned whether the complexity of these programmes makes this possible advantage worthwhile. The absolute benefits from a programme of five-yearly testing after age 25 are only slightly inferior to those achieved by the much more complex policies recommended by the Committee for Gynaecological Cytology, and, in comparison with the latest recommendations, it is more efficient also. A system to ensure that all women receive invitations for screening (and that those who fail to attend receive reminders) should be easy to install if any sort of age-sex register for general practice is in existence. The large volume of rather haphazard incidental testing in relation to pregnancy and family planning might then be drastically curtailed.
